After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Breast cancer classed as HER2-positive - defined as an immunohistochemical ... in PFS with Enhertu compared to chemo in patients with HR-positive disease and a 55% improvement on the same measure ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive ... ER/HER2 concurrent treatment provides significantly better outcomes in HR+/HER2+ advanced breast cancer ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

SYNC, its first homegrown CAR-T therapy, one of the first to show promise in treating certain types of brain cancers. This ...

Source: Getty Images Phase 2 trial results support further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer, according to researchers. The ...